Robert L Bettiker1, David E Koren2, Jeffrey M Jacobson1,3,4. 1. Department of Medicine. 2. Temple University Hospital, Philadelphia, Pennsylvania, USA. 3. Department of Neuroscience. 4. Center for Translational AIDS Research, Lewis Katz School of Medicine at Temple University, Philadelphia.
Abstract
PURPOSE OF REVIEW: Antiretroviral options for patients infected with multiclass resistant HIV-1 warrant the development of new agents with unique mechanisms of action and modes of delivery. Here we review one such agent, ibalizumab, a parenteral CD4 postattachment inhibitor that has demonstrated efficacy as part of combination antiretroviral therapy in the treatment of HIV-1. RECENT FINDINGS: In a phase III clinical trial in HIV-infected participants with multiclass antiretroviral drug resistance, the intravenous administration of ibalizumab led to declines in plasma HIV-1 RNA more than 0.5 log in 83% of participants at 1 week. An optimized background antiretroviral regimen was then added, and plasma HIV-1 RNA became less than 50 copies/ml in 43% of participants at 24 weeks. Adverse effects of ibalizumab were uncommon and generally low grade. Ibalizumab was approved by the US Food and Drug Administration on March 16, 2018, under the trade name Trogarzo. SUMMARY: Ibalizumab has demonstrated both safety and efficacy in the treatment of HIV-1 infection. Its primary use will be in the setting of multidrug resistant virus as part of combination antiretroviral therapy. Further enhancements of ibalizumab to prolong its clearance and broaden its activity are in development.
PURPOSE OF REVIEW: Antiretroviral options for patients infected with multiclass resistant HIV-1 warrant the development of new agents with unique mechanisms of action and modes of delivery. Here we review one such agent, ibalizumab, a parenteral CD4 postattachment inhibitor that has demonstrated efficacy as part of combination antiretroviral therapy in the treatment of HIV-1. RECENT FINDINGS: In a phase III clinical trial in HIV-infectedparticipants with multiclass antiretroviral drug resistance, the intravenous administration of ibalizumab led to declines in plasma HIV-1 RNA more than 0.5 log in 83% of participants at 1 week. An optimized background antiretroviral regimen was then added, and plasma HIV-1 RNA became less than 50 copies/ml in 43% of participants at 24 weeks. Adverse effects of ibalizumab were uncommon and generally low grade. Ibalizumab was approved by the US Food and Drug Administration on March 16, 2018, under the trade name Trogarzo. SUMMARY:Ibalizumab has demonstrated both safety and efficacy in the treatment of HIV-1 infection. Its primary use will be in the setting of multidrug resistant virus as part of combination antiretroviral therapy. Further enhancements of ibalizumab to prolong its clearance and broaden its activity are in development.
Authors: Jessica M Fogel; Mariya V Sivay; Vanessa Cummings; Ethan A Wilson; Stephen Hart; Theresa Gamble; Oliver Laeyendecker; Reinaldo E Fernandez; Carlos Del Rio; D Scott Batey; Kenneth H Mayer; Jason E Farley; Laura McKinstry; James P Hughes; Robert H Remien; Chris Beyrer; Susan H Eshleman Journal: AIDS Date: 2020-01-01 Impact factor: 4.632
Authors: David E Koren; Volodymyra Fedkiv; Huaqing Zhao; Geena Kludjian; Robert L Bettiker; Ellen Tedaldi; Rafik Samuel Journal: J Int Assoc Provid AIDS Care Date: 2020 Jan-Dec
Authors: Sol Ferrero; Maria D Flores; Connor Short; Cecilia A Vazquez; Lars E Clark; James Ziegenbein; Samantha Zink; Daniel Fuentes; Cristian Payes; María V Batto; Michael Collazo; Cybele C García; Jonathan Abraham; Sandra M Cordo; Jose A Rodriguez; Gustavo Helguera Journal: J Virol Date: 2021-08-10 Impact factor: 5.103